Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor (NYSE: AVTR) delivers essential materials and technologies powering breakthroughs in life sciences and advanced industries. This news hub provides investors and professionals with direct access to official announcements, including product innovations, financial results, and strategic partnerships shaping the future of bioprocessing and semiconductor manufacturing.
Track critical updates across Avantor's core operations: earnings disclosures detailing performance in pharmaceutical solutions, regulatory filings impacting global supply chains, and advancements in sustainable production methods like their viral vector processing systems. Discover how developments in brands like J.T. Baker and Macron Fine Chemicals influence research and manufacturing efficiency worldwide.
Our curated news collection serves as a decision-making tool for monitoring Avantor's role in enabling scientific progress across 180+ countries. Bookmark this page for real-time insights into leadership changes, facility expansions, and emerging applications in gene therapy support systems.
Avantor, Inc. (NYSE: AVTR) reported preliminary unaudited revenues for Q3 2021, totaling $1.83 billion, a significant increase of 14.3% year-over-year, with organic growth at 10.2%. The company anticipates finalizing its Masterflex debt financing in Q4 2021. These preliminary results, reflecting management's current views, are subject to change prior to the official earnings release on October 29, 2021. The unaudited figures have not been reviewed by independent auditors and should not replace full financial statements.
Avantor, Inc. (NYSE: AVTR) will release its third quarter 2021 financial results on October 28, 2021, after market close. A conference call to discuss the results is scheduled for October 29, 2021, at 7:30 a.m. EDT. Interested parties can join by phone or listen to a live webcast via the investors section of our website. The earnings press release will be available on the company’s website.
Avantor announced the pricing of an underwritten offering of 20,833,334 shares of its common stock at $42.00 per share. The offering includes a 30-day option for underwriters to purchase an additional 2,976,190 shares. Proceeds will primarily finance the acquisition of Masterflex from Antylia Scientific and may also support general corporate purposes. The offering is set to close on September 16, 2021, pending customary conditions. Goldman Sachs, Citigroup, and BofA Securities are among the joint book-running managers for this transaction.
Avantor announced plans to offer $750 million of common stock in an underwritten offering, related to a pending acquisition of the Masterflex bioprocessing business. The proceeds will also support debt financing. Underwriters may purchase additional shares within 30 days. The company aims to use net proceeds primarily for the acquisition, or for general corporate purposes if not completed. The offering's managers include Goldman Sachs, Citigroup, and BofA Securities.
Avantor, Inc. (NYSE: AVTR) announced a definitive agreement to acquire Masterflex bioprocessing business from Antylia Scientific for $2.9 billion, netting $2.7 billion after tax benefits. Masterflex, based in Illinois, focuses on peristaltic pumps and single-use fluid transfer technologies, generating approximately $300 million in estimated 2022 revenues. This acquisition aims to enhance Avantor's biopharma offerings, contributing to revenue growth and margin improvement. Completion is expected in Q4 2021, subject to regulatory approvals.
Avantor, Inc. (NYSE: AVTR) announced a multi-year investment to enhance its global hydration capabilities, completing a significant facility expansion in Gliwice, Poland, and initiating further expansion in Aurora, Ohio, projected to finish by mid-2022. This investment aims to support the biopharmaceutical industry's increasing demand for biologics by outsourcing buffer preparation, which can streamline workflows and accelerate therapy production. The expanded facilities will improve Avantor's ability to offer WFI-quality water buffer manufacturing, enhancing support for biopharma manufacturers globally.
Avantor, a global leader in mission-critical products for various industries, announced a virtual investor day scheduled for September 9, 2021, at 9:00 a.m. EDT. The event will be accessible via webcast on their official website, where a replay will also be available post-event. Avantor serves over 225,000 customer locations globally, impacting research and production across biopharma, healthcare, education, and advanced technology sectors. The company emphasizes forward-looking statements, cautioning that these may involve risks and uncertainties.
Avantor, Inc. (NYSE: AVTR) reported robust financial results for Q2 2021, with net sales of $1.86 billion, up 25.7% year-on-year. Net income surged 162.1% to $157.8 million. The company achieved 34.2% growth in Adjusted EBITDA to $366.6 million, with a margin expansion of 125 basis points. Despite two acquisitions, Ritter GMBH and RIM Bio, having no significant impact on quarterly results, the company raised its full-year guidance, reflecting confidence in ongoing momentum across various markets.
Avantor (NYSE: AVTR) announced a quarterly cash dividend of $0.78 per share for its 6.250% Series A Mandatory Convertible Preferred Stock, translating to a rate of 1.560%. This dividend is payable on August 16, 2021 to shareholders of record as of August 1, 2021. As a leading global provider of essential products and services across life sciences and technology sectors, Avantor's substantial footprint serves over 225,000 customer locations in more than 180 countries, underscoring its influence in critical research and development activities.
FAQ
What is the current stock price of Avantor (AVTR)?
What is the market cap of Avantor (AVTR)?
